All

ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV – African Swine Fever Virus – infected pigs
9 September 2021

ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV – African Swine Fever Virus – infected pigs

Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine...

Read the press release
A-Mansia Biotech’s pasteurised Akkermansia muciniphila is the firt next generation bacterium to get green light from EFSA’s cientific council
2 September 2021

A-Mansia Biotech’s pasteurised Akkermansia muciniphila is the firt next generation bacterium to get green light from EFSA’s cientific council

A crucial step has been taken by Belgian company A-Mansia Biotech, a co-spin-off of Wageningen University and UCLouvain. The European Food Safety Authority (EFSA) considers the...

Read the press release
Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials
14 July 2021

Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials

Dopavision, a company pioneering the development of digital therapeutics, today announced the closing of a €12 million Series A financing round. Seventure Partners led the...

Read the press release
The partnership between Nexi and Izicap is strengthening: benefits for Italian Local Merchants
8 July 2021

The partnership between Nexi and Izicap is strengthening: benefits for Italian Local Merchants

Nexi, the leading PayTech in Europe, announces the strengthening of its partnership with Izicap, a Fintech specialized in innovative CRM & Loyalty solutions dedicated to Local...

Read the press release
Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
16 June 2021

Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code the molecular interactions in the gut microbiome impacting...

Read the press release
Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression
15 June 2021

Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression

Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for...

Read the press release
Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors
24 March 2021

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors

Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021

ENTEROME SA, a clinical stage biopharmaceutical...

Read the press release
Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why investors need to think beyond ESG
18 March 2021

Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why investors need to think beyond ESG

Calls for genuine corporate responsibility efforts have been high on the agenda for some time, but the pandemic — and its wide-ranging impact on all organisations, including...

Read more
Viva Wallet, PrestaShop partner to allow localised payments for online merchants
17 March 2021

Viva Wallet, PrestaShop partner to allow localised payments for online merchants

Viva Wallet and PrestaShop have partnered to allow online merchants across Europe and the UK to accept fully localised payments in a few clicks, via the Viva Wallet...

Read more
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
17 March 2021

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse